BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25074413)

  • 1. PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition.
    Zhou W; Jubb AM; Lyle K; Xiao Q; Ong CC; Desai R; Fu L; Gnad F; Song Q; Haverty PM; Aust D; Grützmann R; Romero M; Totpal K; Neve RM; Yan Y; Forrest WF; Wang Y; Raja R; Pilarsky C; de Jesus-Acosta A; Belvin M; Friedman LS; Merchant M; Jaffee EM; Zheng L; Koeppen H; Hoeflich KP
    J Pathol; 2014 Dec; 234(4):502-13. PubMed ID: 25074413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors.
    Escorcia FE; Houghton JL; Abdel-Atti D; Pereira PR; Cho A; Gutsche NT; Baidoo KE; Lewis JS
    Theranostics; 2020; 10(1):151-165. PubMed ID: 31903112
    [No Abstract]   [Full Text] [Related]  

  • 3. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
    Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
    Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine.
    Yeo D; He H; Patel O; Lowy AM; Baldwin GS; Nikfarjam M
    BMC Cancer; 2016 Jan; 16():24. PubMed ID: 26774265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma.
    Ito M; Codony-Servat C; Codony-Servat J; Lligé D; Chaib I; Sun X; Miao J; Sun R; Cai X; Verlicchi A; Okada M; Molina-Vila MA; Karachaliou N; Cao P; Rosell R
    Cell Commun Signal; 2019 Oct; 17(1):137. PubMed ID: 31660987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth.
    Luna J; Boni J; Cuatrecasas M; Bofill-De Ros X; Núñez-Manchón E; Gironella M; Vaquero EC; Arbones ML; de la Luna S; Fillat C
    Gut; 2019 Aug; 68(8):1465-1476. PubMed ID: 30343272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative characterization of the HGF/Met and MSP/Ron systems in primary pancreatic adenocarcinoma.
    Vanderwerff BR; Church KJ; Kawas LH; Harding JW
    Cytokine; 2019 Nov; 123():154762. PubMed ID: 31254927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FER mediated HGF-independent regulation of HGFR/MET activates RAC1-PAK1 pathway to potentiate metastasis in ovarian cancer.
    Fan G
    Small GTPases; 2020 May; 11(3):155-159. PubMed ID: 29099290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.
    Wu DW; Wu TC; Chen CY; Lee H
    Clin Cancer Res; 2016 Nov; 22(21):5370-5382. PubMed ID: 27178741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma.
    Ong CC; Jubb AM; Jakubiak D; Zhou W; Rudolph J; Haverty PM; Kowanetz M; Yan Y; Tremayne J; Lisle R; Harris AL; Friedman LS; Belvin M; Middleton MR; Blackwood EM; Koeppen H; Hoeflich KP
    J Natl Cancer Inst; 2013 May; 105(9):606-7. PubMed ID: 23535073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.
    Nakade J; Takeuchi S; Nakagawa T; Ishikawa D; Sano T; Nanjo S; Yamada T; Ebi H; Zhao L; Yasumoto K; Matsumoto K; Yonekura K; Yano S
    J Thorac Oncol; 2014 Jun; 9(6):775-83. PubMed ID: 24828661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of group 1 p21-activated kinases suppresses pancreatic stellate cell activation and increases survival of mice with pancreatic cancer.
    Yeo D; Phillips P; Baldwin GS; He H; Nikfarjam M
    Int J Cancer; 2017 May; 140(9):2101-2111. PubMed ID: 28109008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of Ezrin, HGF, C-met in pancreatic cancer and non-cancerous pancreatic tissues of rats.
    Tan XG; Yang ZL
    Hepatobiliary Pancreat Dis Int; 2010 Dec; 9(6):639-44. PubMed ID: 21134835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion.
    Cao HH; Cheng CY; Su T; Fu XQ; Guo H; Li T; Tse AK; Kwan HY; Yu H; Yu ZL
    Mol Cancer; 2015 May; 14():103. PubMed ID: 25971889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of P21-activated kinases 1 and 4 synergistically suppresses the growth of pancreatic cancer by stimulating anti-tumour immunity.
    Ma Y; Dumesny C; Dong L; Ang CS; Asadi K; Zhan Y; Nikfarjam M; He H
    Cell Commun Signal; 2024 May; 22(1):287. PubMed ID: 38797819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
    Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
    Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.
    Knowles LM; Stabile LP; Egloff AM; Rothstein ME; Thomas SM; Gubish CT; Lerner EC; Seethala RR; Suzuki S; Quesnelle KM; Morgan S; Ferris RL; Grandis JR; Siegfried JM
    Clin Cancer Res; 2009 Jun; 15(11):3740-50. PubMed ID: 19470725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1.
    Chen H; Lin C; Peng T; Hu C; Lu C; Li L; Wang Y; Han R; Feng M; Sun F; He Y
    Cell Death Dis; 2020 Feb; 11(2):111. PubMed ID: 32041944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: antiangiogenic implications in pancreatic cancer.
    Patel MB; Pothula SP; Xu Z; Lee AK; Goldstein D; Pirola RC; Apte MV; Wilson JS
    Carcinogenesis; 2014 Aug; 35(8):1891-900. PubMed ID: 24876152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells.
    Ong CC; Jubb AM; Haverty PM; Zhou W; Tran V; Truong T; Turley H; O'Brien T; Vucic D; Harris AL; Belvin M; Friedman LS; Blackwood EM; Koeppen H; Hoeflich KP
    Proc Natl Acad Sci U S A; 2011 Apr; 108(17):7177-82. PubMed ID: 21482786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.